Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001087294-26-000049
Filing Date
2026-05-08
Accepted
2026-05-08 17:02:07
Documents
61
Period of Report
2026-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q cpix-20260331.htm   iXBRL 10-Q 676861
2 EX-31.1 a2026q1-exhibit311.htm EX-31.1 12506
3 EX-31.2 a2026q1-exhibit312.htm EX-31.2 12499
4 EX-32.1 a2026q1-exhibit321.htm EX-32.1 6763
  Complete submission text file 0001087294-26-000049.txt   4503656

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT cpix-20260331.xsd EX-101.SCH 35812
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT cpix-20260331_cal.xml EX-101.CAL 52538
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT cpix-20260331_def.xml EX-101.DEF 125505
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT cpix-20260331_lab.xml EX-101.LAB 454508
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT cpix-20260331_pre.xml EX-101.PRE 317669
64 EXTRACTED XBRL INSTANCE DOCUMENT cpix-20260331_htm.xml XML 438518
Mailing Address 1600 WEST END AVENUE SUITE 1300 NASHVILLE TN 37203
Business Address 1600 WEST END AVENUE SUITE 1300 NASHVILLE, TN 37203 615-255-0068
CUMBERLAND PHARMACEUTICALS INC (Filer) CIK: 0001087294 (see all company filings)

EIN.: 621765329 | State of Incorp.: TN | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33637 | Film No.: 26959524
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)